SLC5A2 and diabetes mellitus: Some studies have concluded that SGLT2 inhibitors, when administered to patients with type 2 diabetes mellitus, ameliorate insulin resistance (as measured by HOMA-IR) primarily by increasing glucose uptake in skeletal muscle and promoting lipolysis in adipose tissue.